F-1: Galmed Pharmaceuticals Seeks to Raise Up to $10 Million Through Standby Equity Purchase Agreement

Galmed Pharmaceuticals enters into a Standby Equity Purchase Agreement with YA II PN, LTD. to potentially raise up to $10 million through the sale of ordinary shares.

Summary

• Galmed Pharmaceuticals has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., allowing the company to sell up to $10 million of its ordinary shares to YA over a 36-month period.
• The company has issued 7,892 ordinary shares to YA as an initial commitment fee and will issue an additional 23,674 ordinary shares in three installments as subsequent commitment fees.
• YA may purchase up to 385,101 additional ordinary shares (Advance Shares) at a price equal to 97% of the lowest of the three daily VWAPs during a pricing period.
• Galmed will not receive any proceeds from the resale of shares by YA but may receive up to $10 million in gross proceeds from the sale of Advance Shares to YA.
• The company intends to use any proceeds from the sale of ordinary shares under the Purchase Agreement for continued development of its pipeline products, advancement of new programs, business development activities, and general corporate purposes.
• The Purchase Agreement includes an Ownership Limitation, preventing YA from owning more than 4.99% of the outstanding ordinary shares.
• As of August 30, 2024, Galmed had 643,694 ordinary shares outstanding, with 47,173 held by non-affiliates.
• If all 416,667 ordinary shares are issued, they would represent approximately 5.4% of the total outstanding shares and 5.8% of the outstanding shares held by non-affiliates as of August 30, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The announcement details a financing agreement, which provides potential funding but also introduces dilution risk. The terms are fairly standard for this type of agreement.

Positives

• The SEPA provides Galmed with a potential source of funding up to $10 million.
• The company has flexibility in determining the timing and amount of sales of ordinary shares to YA, subject to market conditions.
• YA is prohibited from engaging in short sales or hedging transactions with respect to Galmed's ordinary shares during the term of the Purchase Agreement.
• Galmed retains the right to terminate the Purchase Agreement at any time without cost or penalty.

Negatives

• The company will not receive any proceeds from the resale of shares by YA.
• The actual amount of proceeds that Galmed may receive is uncertain and depends on market conditions and the price of its ordinary shares.
• The issuance of ordinary shares to YA will dilute existing shareholders' economic and voting interests.
• The market price of Galmed's ordinary shares could decline due to the resale of shares by YA.
• Galmed may need to register additional shares for resale if it needs to sell more shares to YA than are currently registered to receive the full $10 million commitment.

Risks

• The actual number of shares Galmed will sell under the Purchase Agreement is unpredictable.
• Limitations in the Purchase Agreement, including the Ownership Limitation, could prevent Galmed from raising the full Commitment Amount.
• The resale by YA of a significant amount of shares could cause the market price of Galmed's ordinary shares to decline and be highly volatile.
• Galmed may require additional financing to sustain its operations.
• The sale of a substantial amount of ordinary shares could adversely affect the prevailing market price of Galmed's ordinary shares.
• Management will have broad discretion as to the use of the net proceeds from the Purchase Agreement.

Future Outlook

Galmed expects that any proceeds received from sales of ordinary shares under the Purchase Agreement will be used for continued development of its pipeline products, as well as the advancement of new programs, business development activities, and general corporate purposes.

Industry Context

This type of financing agreement is common for small cap biotech companies to raise capital, but it can be dilutive to existing shareholders.

Comparison to Industry Standards

• Similar standby equity purchase agreements are used by companies like Mustang Bio and Diffusion Pharmaceuticals to secure funding.
• The 97% of VWAP pricing is a fairly standard discount for these types of agreements.
• The 4.99% ownership limitation is also common to avoid triggering certain regulatory thresholds.

Stakeholder Impact

• Shareholders may experience dilution of their economic and voting interests.
• The market price of Galmed's ordinary shares could be affected by the resale of shares by YA.
• The company's ability to fund its operations and development programs could be enhanced.

Next Steps

• Galmed may elect to issue Advance Shares to YA from time to time during the 36-month commitment period.
• YA may resell the ordinary shares included in the prospectus in a number of different ways and at varying prices.
• Galmed may need to file additional registration statements to register additional shares for resale if it needs to sell more shares to YA than are currently registered.

Key Dates

Keywords

Standby Equity Purchase Agreement, Ordinary Shares, YA II PN, LTD., Capital Raise, Dilution, Commitment Shares, Advance Shares, Galmed Pharmaceuticals, Funding, SEPA